NasdaqGS:MRNABiotechs
Why Moderna (MRNA) Is Down 6.6% After Lowering 2025 Revenue Outlook on Delayed U.K. Shipments
Moderna recently lowered its 2025 revenue guidance by US$300 million due to a shift in timing for U.K. COVID-19 vaccine shipments, moving that revenue into early 2026, and released second-quarter results showing a year-over-year decline in revenue to US$142 million and a net loss of US$825 million.
While the U.K. shipment timing reduces near-term visibility, the total value of Moderna's long-term contract with the U.K. remains unchanged, highlighting the continuing demand for its COVID-19...